131 related articles for article (PubMed ID: 38854182)
1. Clinical Characteristics of Psoriasis Cases Treated by Biologics With an Extended Administration Interval: A Single-Center, Retrospective Observational Study.
Nozaki H; Honma M; Ishida-Yamamoto A
Cureus; 2024 May; 16(5):e59969. PubMed ID: 38854182
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
[TBL] [Abstract][Full Text] [Related]
3. Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis.
Wu MY; Yu CL; Yang SJ; Chi CC
J Am Acad Dermatol; 2020 Jan; 82(1):101-109. PubMed ID: 31400455
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
Pinter A; Puig L; Schäkel K; Reich A; Zaheri S; Costanzo A; Tsai TF; Smith SD; Lynde C; Brnabic A; Reed C; Hill J; Schuster C; Riedl E; Paul C
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.
Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO).
Travaglini M; Maul JT; Kors C; Zaheri S; Gerwien J; Müller M; Brnabic A; Sabatino S; Schuster C; Tsai TF
Clin Cosmet Investig Dermatol; 2023; 16():2971-2983. PubMed ID: 37881205
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
[TBL] [Abstract][Full Text] [Related]
8. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
9. Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry.
McLean RR; Sima AP; Beaty S; Jones EA; Eckmann T; Low R; McClung L; Spitzer RL; Stark J; Armstrong A
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2753-2768. PubMed ID: 37759099
[TBL] [Abstract][Full Text] [Related]
10. Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study.
van Bezooijen JS; van Doorn MBA; Schreurs MWJ; Koch BCP; Te Velthuis H; Prens EP; van Gelder T
Ther Drug Monit; 2017 Aug; 39(4):379-386. PubMed ID: 28570371
[TBL] [Abstract][Full Text] [Related]
11. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
[TBL] [Abstract][Full Text] [Related]
12. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
[TBL] [Abstract][Full Text] [Related]
13. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
Takamura S; Takahashi A; Inoue Y; Teraki Y
J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
[TBL] [Abstract][Full Text] [Related]
14. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
Graier T; Weger W; Jonak C; Sator P; Zikeli C; Prillinger K; Sassmann C; Gruber B; Saxinger W; Ratzinger G; Painsi C; Mlynek A; Häring N; Sadoghi B; Trattner H; Müllegger R; Quehenberger F; Salmhofer W; Wolf P
Sci Rep; 2022 Sep; 12(1):15078. PubMed ID: 36064563
[TBL] [Abstract][Full Text] [Related]
16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
17. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis.
Bagel J; Nelson E; Zapata J; Hetzel A
Dermatol Ther (Heidelb); 2020 Dec; 10(6):1383-1396. PubMed ID: 33048333
[TBL] [Abstract][Full Text] [Related]
19. An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12.
Papp K; Maari C; Cauthen A; Gooderham M; Spelman L; Yamanaka K; Polzer P; Zhang L; Osuntokun O; Augustin M
Br J Dermatol; 2020 Jul; 183(1):52-59. PubMed ID: 31545506
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]